ArticleJournal of lipid research2026
A TRAK2-KIF5B complex mediates microtubule-based LDL vesicle transport during endothelial transcytosis.
Article in Journal of lipid research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transendothelial transport of LDL into the vascular intima is an early step in atherogenesis, yet the intracellular machinery governing endothelial LDL transcytosis remains incompletely understood. We sought regulators of LDL-containing vesicle trafficking and their mechanisms. Transcriptomic profiles of human abdominal aortic aneurysm specimens and normal aortas were analyzed to nominate candidates. Among 3,641 differentially expressed genes, trafficking kinesin protein 2 (TRAK2) was prioritized. In human umbilical vein endothelial cells, TRAK2 was silenced by siRNA or overexpressed by plasmid transfection. LDL transcytosis was quantified by apical-to-basolateral flux in transwell assays and by basolateral exocytic events using total internal reflection fluorescence microscopy. TRAK2 knockdown reduced transcytosis in both assays (P < 0.05), whereas overexpression did not enhance transcytosis (P = 0.61). Findings were consistent across independent experiments and assay platforms. Fluorescent LDL uptake was unchanged, indicating a post-internalization role and suggesting TRAK2 promotes basolateral transport. Live-cell confocal imaging showed LDL vesicles colocalized with TRAK2 and moved directionally along microtubules. TRAK2 knockdown abolished LDL-induced responses of kinesin family member 13A (KIF13A) and further reduced KIF13B expression, while KIF5B remained LDL-responsive. Coimmunoprecipitation identified a TRAK2-KIF5B complex, but not interactions with KIF13A or KIF13B. Consistently, KIF5B depletion reduced LDL transcytosis (P < 0.05), and LDL vesicles frequently colocalized with KIF5B during microtubule-based transport. These findings identify a TRAK2-KIF5B motor-adapter axis that mediates microtubule-dependent trafficking of LDL-containing vesicles during endothelial transcytosis, defining an intracellular control point for LDL delivery to the intima and a potential target to modulate early atherogenic processes.
Indexed as
Identifiers
42767506What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.